Search hospitals > South Carolina > Easley
Prisma Health Cancer Institute - Easley
Claim this profileEasley, South Carolina 29640
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
223 reported clinical trials
5 medical researchers
Summary
Prisma Health Cancer Institute - Easley is a medical facility located in Easley, South Carolina. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Prisma Health Cancer Institute - Easley is involved with conducting 223 clinical trials across 402 conditions. There are 5 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and Suzanne R. Fanning.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Ki Chung, MDPrisma Health Cancer Institute - Eastside5 years of reported clinical research
Expert in Cancer
Expert in Tumors
95 reported clinical trials
196 drugs studied
Aniket SahaBI-LO Charities Children's Cancer Center7 years of reported clinical research
Expert in Brain Tumor
Expert in Tumors
58 reported clinical trials
119 drugs studied
Jeffrey K. GiguerePrisma Health Cancer Institute - Faris7 years of reported clinical research
Studies Cancer
Studies Breast Cancer
26 reported clinical trials
64 drugs studied
Suzanne R. FanningPrisma Health Cancer Institute - Eastside1 year of reported clinical research
Studies Leukemia
Studies Lymphoma
11 reported clinical trials
35 drugs studied
Clinical Trials running at Prisma Health Cancer Institute - Easley
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Colorectal Cancer
Acute Myeloid Leukemia
Bladder Cancer
Tumors
Leukemia
Pancreatic Neuroendocrine Tumors
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Prisma Health Cancer Institute - Easley?
Prisma Health Cancer Institute - Easley is a medical facility located in Easley, South Carolina. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Prisma Health Cancer Institute - Easley is involved with conducting 223 clinical trials across 402 conditions. There are 5 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and Suzanne R. Fanning.